Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Armelle Meunier, Vio Buchete, Laure Marignol
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
MicroRNAs and the cell cycle
10.1016/j.bbadis.2011.02.002 · 2011
A direct role for small non-coding RNAs in DNA damage response
10.1016/j.tcb.2013.09.008 · 2014
MiRNAs and apoptosis: RNAs to die for
10.1038/sj.onc.1209912 · 2006
The hypoxic cell: a target for selective cancer therapy—eighteenth Bruce F. Cain memorial award lecture
1999
Emergence of miR-34a in radiation therapy
10.1016/j.critrevonc.2016.11.017 · 2017
Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells
10.1667/rr2703.1 · 2012
Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells
10.1002/pros.21272 · 2011
Radiation modulation of microRNA in prostate cancer cell lines
10.1002/pros.20827 · 2008
MiRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1
10.1158/0008-5472.can-13-1657 · 2013
Hypoxia-responsive mir-301a and mir-301b promote radioresistance of prostate cancer cells via downregulating NDRG2
10.12659/msm.896832 · 2016
MicroRNAs as putative mediators of treatment response in prostate cancer
10.1038/nrurol.2012.104 · 2012
Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment
10.3892/or.2014.2988 · 2014
Recent advances in developing molecular tools for targeted genome engineering of mammalian cells
10.5483/bmbrep.2015.48.1.165 · 2015
Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability
10.1038/nrc2344 · 2008
Hypoxia in prostate cancer: a powerful shield against tumour destruction?
10.1016/j.ctrv.2008.01.006 · 2008
Isogenic radiation resistant cell lines: development and validation strategies
10.3109/09553002.2014.873557 · 2014
A new human prostate carcinoma cell line, 22Rv1
10.1007/s11626-999-0115-4 · 1999
Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells
10.1038/srep34796 · 2016
The mutational landscape of prostate cancer
10.1016/j.eururo.2013.05.029 · 2013
Desperately seeking microRNA targets
10.1038/nsmb.1921 · 2010
Clonogenic assay of cells in vitro
10.1038/nprot.2006.339 · 2006
MicroRNA target predictions across seven Drosophila species and comparison to mammalian targets
10.1371/journal.pcbi.0010013 · 2005
Prediction of both conserved and nonconserved microRNA targets in animals
10.1093/bioinformatics/btm595 · 2008
MiRNA deregulation in cancer cells and the tumor microenvironment
10.1158/2159-8290.cd-15-0893 · 2016
MicroRNAs and their impact on radiotherapy for cancer
10.1667/rr14370.1 · 2016
Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer
2016
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT
10.4161/cc.8.17.9387 · 2009
MiR-210–micromanager of the hypoxia pathway
10.1016/j.molmed.2010.03.004 · 2010
A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia
10.1371/journal.pone.0125560 · 2015
MiR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance
10.1371/journal.pone.0098597 · 2014
Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role
10.2147/ott.s119027 · 2016
Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer
10.3892/ijo.2014.2437 · 2014
Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening
10.18632/oncotarget.12241 · 2016
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
10.1007/s13277-011-0154-9 · 2011
Identification of radiation-induced microRNA transcriptome by next-generation massively parallel sequencing
10.1093/jrr/rrt014 · 2013
MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN
10.1186/1471-2407-10-367 · 2010
Onco-miR-130 promotes cell proliferation and migration by targeting TGFbetaR2 in gastric cancer
10.18632/oncotarget.9936 · 2016
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab
10.1186/1479-5876-11-218 · 2013
Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer
10.1002/pros.22469 · 2012
Expression of dicer and its related miRNAs in the progression of prostate cancer
10.1371/journal.pone.0120159 · 2015
The role of the H-ras oncogene in radiation resistance and metastasis
10.1016/0360-3016(90)90407-b · doi-reference
Increased radioresistance of ejras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation
10.1002/ijc.2910530222 · doi-reference
Radioresistance induced by oncogenic transformation
10.2307/3577713 · doi-reference
Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest
10.1667/0033-7587(2000)153[0371:irimap]2.0.co;2 · doi-reference
Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma
10.1126/science.2466340 · doi-reference
RAS oncogenes: weaving a tumorigenic web
10.1038/nrc3106 · doi-reference
Targeting RAS signalling pathways in cancer therapy
10.1038/nrc969 · doi-reference
RAS oncogenes: the first 30 years
10.1038/nrc1097 · doi-reference
Enhanced RASGEF1A expression is involved in the growth and migration of intrahepatic cholangiocarcinoma
10.1158/1078-0432.ccr-06-0783 · doi-reference
RasGEF1A and RasGEF1B are guanine nucleotide exchange factors that discriminate between Rap GTP-binding proteins and mediate Rap2-specific nucleotide exchange
10.1111/j.1742-4658.2009.07166.x · doi-reference
RNF12 is an X-Encoded dose-dependent activator of X chromosome inactivation
10.1016/j.cell.2009.10.034 · doi-reference
Ubiquitin ligase RLIM modulates telomere length homeostasis through a proteolysis of TRF1
10.1074/jbc.m806702200 · doi-reference
RLIM inhibits functional activity of LIM homeodomain transcription factors via recruitment of the histone deacetylase complex
10.1038/11970 · doi-reference
MiR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer
10.1016/j.radonc.2011.05.063 · doi-reference
MiR-210: a potential therapeutic target against radiation-induced enteropathy
10.1016/j.radonc.2013.10.030 · doi-reference
Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice
10.1186/1748-717x-8-102 · doi-reference
Profiling of circulating microRNAs for prostate cancer biomarker discovery
10.1007/s13346-013-0169-4 · doi-reference
Prognostic impact of hypoxia-inducible miRNA-210 in patients with lung adenocarcinoma
10.1155/2015/316745 · doi-reference
Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer
10.1371/journal.pone.0090952 · doi-reference
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia
10.1371/journal.pone.0069239 · doi-reference